Exelixis | EXEL - نسبة السعر إلى الأرباح





Pe تغيير تاريخ
Acadia Pharmaceuticals 9.52 1.81 2026-09
Agios Pharmaceuticals 3.56 0 2026-03
Akebia Therapeutics 1.63K 1.6K 2025-12
Amgen 18.6 0.53 2026-09
AstraZeneca 24.63 0.71 2026-09
Bayer 4.61 0.47 2026-09
BioMarin Pharmaceutical 53.62 32.55 2026-09
Bristol-Myers Squibb 10.44 5.7 2026-09
Eisai 30.24 3.68 2026-09
Eli Lilly 64.5 31.61 2026-09
Exelixis 18.43 0.41 2026-09
Genmab 16.04 1.05 2026-06
Glaxosmithkline 15.17 0.08 2026-09
Incyte 54.54 40.08 2026-09
Ionis Pharmaceuticals 396.15 79.28 2022-09
Merck 34.36 2.11 2026-09
Moderna 27.22 14.51 2023-06
Neurocrine Biosciences 83.17 61.07 2026-09
Novartis 19.17 3.24 2026-09
Pfizer 15.2 3.72 2026-09
Puma Biotechnology 13.93 44.88 2024-06
Sanofi 21.74 11.35 2026-09
Takeda 21.04 3.36 2026-09
Xencor 29.92 3.22 2022-09